uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Estrogen receptor beta 1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
Karolinska Inst, Dept Biosci & Nutr, SE-14183 Huddinge, Sweden..
Karolinska Inst, Dept Biosci & Nutr, SE-14183 Huddinge, Sweden..
Karolinska Inst, Dept Biosci & Nutr, SE-14183 Huddinge, Sweden..
Karolinska Inst, Dept Biosci & Nutr, SE-14183 Huddinge, Sweden..
Show others and affiliations
2017 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 58, no 2, 418-427 p.Article in journal (Refereed) Published
Abstract [en]

Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor beta (ER beta) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ER beta 1 expression analysis in primary DLBCL's by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERb1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERb1 is an interesting future therapeutic target for treatment of DLBCL, and that ERb1 expression can be used as a prognostic marker.

Place, publisher, year, edition, pages
2017. Vol. 58, no 2, 418-427 p.
Keyword [en]
Estrogen, gender difference, immunohistochemistry, lymphoma growth, receptor expression
National Category
Cancer and Oncology Hematology
Identifiers
URN: urn:nbn:se:uu:diva-311474DOI: 10.1080/10428194.2016.1193853ISI: 000388601000021PubMedID: 27357538OAI: oai:DiVA.org:uu-311474DiVA: diva2:1060605
Funder
Swedish Cancer SocietyAFA InsuranceSwedish Childhood Cancer Foundation
Available from: 2016-12-29 Created: 2016-12-28 Last updated: 2016-12-29Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Amini, Rose MarieEnblad, Gunilla
By organisation
Clinical and experimental pathologyExperimental and Clinical Oncology
In the same journal
Leukemia and Lymphoma
Cancer and OncologyHematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 167 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf